Skip to main content

Table 3 Subgroup analysis of progression-free survival

From: Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

 

Olaratumab + Liposomal Doxorubicin (n = 62)

Liposomal Doxorubicin(n = 61)

Hazard Ratioa

 

No.

Events

Median, monthsb

95% CIb

No.

Events

Median, monthsb

95% CIb

HR

95% CI

Stratification factor (from IVRS)

          

Platinum-refractory

15

12

5.5

(1.6–9.2)

16

13

3.7

(1.9–9.2)

0.85

(0.38–1.91)

Platinum-resistant

47

37

3.7

(1.9–6.2)

45

34

4.0

(2.7–7.8)

1.13

(0.71–1.80)

  1. CI, confidence interval; IVRS, interactive voice response system
  2. aHazard ratio is expressed as olaratumab+liposomal doxorubicin/liposomal doxorubicin and estimated from Cox model
  3. bEstimated by the Kaplan-Meier method